According to the official website of the Shanghai Stock Exchange STAR Market, Trinomab’s IPO registration has become effective, and the company is about to be officially listed on the STAR Market. Trinomab adopted the fifth set of listing standards. Founded…
In May 2026, SYH2095 Tablets, co-developed by CSPC Pharmaceutical Group and Yingchuang Pharmaceutical, received approval from the CDE to conduct clinical trials for advanced malignant tumors. In April of this year, the drug had already received approval from the U.S.…
In March 2026, SYS6051, developed by CSPC Pharmaceutical Group’s Jushi Biopharmaceutical, received clinical trial approval in China for the indication of advanced solid tumors. The drug has also received clearance from the U.S. FDA to conduct clinical trials. SYS6051 is…
In March 2026, SYH2059 Inhalation Powder received a clinical trial tacit approval in China for the indication of pulmonary fibrosis. SYH2059 is a highly selective phosphodiesterase 4B (PDE4B) inhibitor developed by CSPC Pharmaceutical Group. Preclinical studies have shown that SYH2059…
In January 2026, CSPC Pharmaceutical Group’s SYS6055 Injection received clinical trial approval for the treatment of relapsed/refractory aggressive B-cell lymphoma. According to the Insight database, this is the first in vivo CAR-T product approved by the CDE to enter registrational…
On June 11, the CDE official website showed that a new indication New Drug Application (NDA) for Biokin Pharmaceutical’s BL-B01D1 for Injection has been accepted. Based on clinical trial progress, the Insight database speculates that the indication is for unresectable…
On June 11, the CDE official website showed that a New Drug Application (NDA) for BrightGene Pharmaceutical’s BGM0504 Injection has been accepted. According to the Insight database, the proposed indication is for overweight or obesity. BGM0504 is a GLP-1 and…
On June 11, Kangning Jierui announced that the Phase III clinical study (KN026-003, NCT05838066) of Annitumumab (KN026) in combination with docetaxel (albumin-bound) (HB1801) as a first-line treatment for HER2-positive advanced breast cancer has met its primary endpoint of progression-free survival…
On June 11, the NMPA official website showed that Akeso’s Gumokimab has been approved for marketing for the first time in China for the treatment of moderate-to-severe plaque psoriasis. Notably, this is the second innovative drug in the autoimmune disease…
On June 11, the NMPA official website showed that Merck’s Clesrovimab (MK-1654) Injection has been approved for marketing in China. The indication is for the prevention of lower respiratory tract infection caused by respiratory syncytial virus (RSV) in neonates and…